Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

Conditions:Blood Cancer, Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Age Range:18 - Any
Start Date:October 2015
End Date:October 2020
Contact:Rachel Couchenour

Use our guide to learn which trials are right for you!

Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

Phase 1 will investigate maximum tolerated dose of OXi4503 as a single agent and in
combination with intermediate-dose cytarabine in subjects with relapsed/refractory AML or

Phase 2 will investigate overall response rate of OXi4503 in combination with
intermediate-dose cytarabine in 1) subjects with MDS after failure of 1 prior hypomethylating
agent (Arm A) and 2) subjects with relapsed and refractory AML after treatment failure of up
to 1 prior chemotherapy regimen (Arm B).

Phase 1 dose escalation component will assess the safety, PK/PD, and preliminary efficacy of
OXi4503 as a single agent in subjects with relapsed/refractory AML and MDS, and the safety
and PK/PD of the combination of OXi4503 with intermediate-dose cytarabine in subjects with

Phase 2 will assess the preliminary efficacy of the OXi4503+cytarabine combination in 2

Inclusion Criteria:

1. Provide informed consent

2. ≥ 18 years of age

3. Phase 1 (dose escalation) subjects must have either:

- AML that has failed to achieve complete remission or morphologic complete
remission or

- MDS - Marrow blasts must be > 5% and disease failed at least 1 prior
hypomethylating agent

4. Phase 2 (expansion) subjects must have either MDS or relapsed/refractory AML

5. Eastern Cooperative Oncology Group performance status 0, 1, or 2

6. Total bilirubin ≤ 2

7. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5
times upper limit of normal (ULN)

8. Serum creatinine < 2.5 times ULN

9. Prothrombin time (PT)/international normalized ratio and (PTT) in normal range ± 25%

10. Women of child-bearing potential

11. Males with female partners of child-bearing potential must agree to use
physician-approved contraceptive methods

Exclusion Criteria:

1. Acute promyelocytic leukemia

2. Absolute peripheral blood myeloblast count greater than 20,000/mm3

3. Uncontrolled hypertension

4. History of congenital long QT syndrome or torsades de pointes

5. Pathologic bradycardia or heart block

6. Prolonged baseline QTc

7. Hiistory of ventricular arrhythmia

8. Myocardial infarction and/or new ST elevation

9. Any history of hemorrhagic stroke

10. Symptomatic congestive heart failure

11. Major hemorrhagic event within 28 days

12. Suggestive central nervous system involvement with leukemia

13. Any open wound

14. Pregnant and nursing subjects are excluded

15. Treatment with any anticancer therapy

16. Treatment with colchicine is excluded.

17. Psychiatric disorders that would interfere with consent
We found this trial at
Westwood, Kansas 66205
Principal Investigator: Tara Lin, MD
Phone: 913-945-7547
Westwood, KS
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Christopher Cogle R Cogle, MD
Phone: 352-273-6840
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Gainesville, FL
Click here to add this to my saved trials
10833 Le Conte Ave
Los Angeles, California 90095
(310) 825-4321
Principal Investigator: Gary Schiller, MD
Phone: 310-794-0242
David Geffen School of Medicine, UCLA In 2002 Mr. David Geffen announced a $200 million...
Los Angeles, CA
Click here to add this to my saved trials
1475 NW 12th Ave
Miami, Florida 33136
(305) 243-1000
Principal Investigator: Justin Watts, MD
Phone: 305-243-9899
University of Miami, Sylvester Comprehensive Cancer Center Sylvester Comprehensive Cancer Center integrates all cancer-related activities...
Miami, FL
Click here to add this to my saved trials